☰

Damian J. Junk, Ph.D. - Publications

Affiliations: 
2008 Cancer Biology University of Arizona, Tucson, AZ 
Area:
Cell Biology, Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

11 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Doherty MR, Parvani JG, Tamagno I, Junk DJ, Bryson BL, Cheon HJ, Stark GR, Jackson MW. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. Breast Cancer Research : Bcr. 21: 54. PMID 31036052 DOI: 10.1186/S13058-019-1136-X  0.365
2019 Taylor WR, Fedorka SR, Gad I, Shah R, Alqahtani HD, Koranne R, Kuganesan N, Dlamini S, Rogers T, Al-Hamashi A, Kholodovych V, Barudi Y, Junk D, Rashid MS, Jackson MW, et al. Small-Molecule Ferroptotic Agents with Potential to Selectively Target Cancer Stem Cells. Scientific Reports. 9: 5926. PMID 30976078 DOI: 10.1038/S41598-019-42251-5  0.31
2017 Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML, Ford JM, Stark GR, Jackson MW. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 29229854 DOI: 10.1073/Pnas.1713728114  0.395
2013 Junk DJ, Cipriano R, Stampfer M, Jackson MW. Constitutive CCND1/CDK2 activity substitutes for p53 loss, or MYC or oncogenic RAS expression in the transformation of human mammary epithelial cells. Plos One. 8: e53776. PMID 23390492 DOI: 10.1371/journal.pone.0053776  0.546
2012 Radivoyevitch T, Saunthararajah Y, Pink J, Ferris G, Lent I, Jackson M, Junk D, Kunos CA. dNTP Supply Gene Expression Patterns after P53 Loss. Cancers. 4: 1212-24. PMID 23205301 DOI: 10.3390/Cancers4041212  0.316
2011 Cheon H, Holvey-Bates E, Junk D, Jackson M, Stark G. CS07-5. Loss of p53 increases unphosphorylated STAT1, which induces resistance to DNA damage in cancer cells Cytokine. 56: 52. DOI: 10.1016/J.Cyto.2011.07.342  0.337
2008 Vrba L, Junk DJ, Novak P, Futscher BW. p53 induces distinct epigenetic states at its direct target promoters. Bmc Genomics. 9: 486. PMID 18922183 DOI: 10.1186/1471-2164-9-486  0.759
2008 Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia (New York, N.Y.). 10: 450-61. PMID 18472962 DOI: 10.1593/Neo.08120  0.753
2005 Oshiro MM, Kim CJ, Wozniak RJ, Junk DJ, Muñoz-Rodríguez JL, Burr JA, Fitzgerald M, Pawar SC, Cress AE, Domann FE, Futscher BW. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Research : Bcr. 7: R669-80. PMID 16168112 DOI: 10.1186/Bcr1273  0.627
2004 Watts GS, Oshiro MM, Junk DJ, Wozniak RJ, Watterson S, Domann FE, Futscher BW. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia (New York, N.Y.). 6: 187-94. PMID 15153330 DOI: 10.1593/Neo.3292  0.65
2003 Oshiro MM, Watts GS, Wozniak RJ, Junk DJ, Munoz-Rodriguez JL, Domann FE, Futscher BW. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene. 22: 3624-34. PMID 12789271 DOI: 10.1038/Sj.Onc.1206545  0.643
Show low-probability matches.